Tomoteru Yamasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tomoteru Yamasaki has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Wakana Mori
National Institute for Quantum Science and Technology Inage-ku
16 shared publicationsYiding Zhang
National Institute for Quantum Science and Technology Inage-ku
15 shared publications- Ming-Rong Zhang
National Institutes for Quantum Science and Technology
13 shared publications Nobuki Nengaki
National Institute for Quantum Science and Technology Inage-ku
12 shared publicationsYusuke Kurihara
National Institute for Quantum Science and Technology Inage-ku
10 shared publicationsHidekatsu Wakizaka
Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan
9 shared publications
Latest Publications
- 20 August 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
Development and Preclinical Evaluation of a Novel PET Probe for Phosphodiesterase 7B Imaging in Brain
Phosphodiesterase 7B (PDE7B) is involved in the cAMP-PKA signaling pathway and has been implicated in neurodegenerative disorders. Accordingly, PDE7B represents a promising target for the development of therapeutics to treat such diseases. Recent efforts have led to the discovery of pyrimidinone-based compounds with high affinity and selectivity for PDE7B. In this study, we developed a novel pyrimidinone-based positron emission tomography (PET) probe, [11C]5. In vitro autoradiography using rat brain sections revealed specific binding of [11C]5 in the striatum and thalamus, consistent with the known distribution of PDE7B. Baseline PET scans showed relatively low brain uptake of [11C]5, except in the olfactory bulb. Pretreatment with elacridar, a potent dual inhibitor of drug efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), enhanced the brain uptake of [11C]5, resulting in further specific in vivo binding in the olfactory bulb and striatum. In conclusion, although the brain permeability of [11C]5 was limited by P-gp and BCRP, [11C]5 demonstrated specific binding to PDE7B, both in vitro and in vivo, supporting its potential utility for imaging PDE7B in the central nervous system.
- 20 August 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
Development and Preclinical Evaluation of a Novel PET Probe for Phosphodiesterase 7B Imaging in Brain
Phosphodiesterase 7B (PDE7B) is involved in the cAMP-PKA signaling pathway and has been implicated in neurodegenerative disorders. Accordingly, PDE7B represents a promising target for the development of therapeutics to treat such diseases. Recent efforts have led to the discovery of pyrimidinone-based compounds with high affinity and selectivity for PDE7B. In this study, we developed a novel pyrimidinone-based positron emission tomography (PET) probe, [11C]5. In vitro autoradiography using rat brain sections revealed specific binding of [11C]5 in the striatum and thalamus, consistent with the known distribution of PDE7B. Baseline PET scans showed relatively low brain uptake of [11C]5, except in the olfactory bulb. Pretreatment with elacridar, a potent dual inhibitor of drug efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), enhanced the brain uptake of [11C]5, resulting in further specific in vivo binding in the olfactory bulb and striatum. In conclusion, although the brain permeability of [11C]5 was limited by P-gp and BCRP, [11C]5 demonstrated specific binding to PDE7B, both in vitro and in vivo, supporting its potential utility for imaging PDE7B in the central nervous system.
- Open Access
Native receptor-targeted chemogenetics enables cell-type-specific inhibition of endogenous receptors in freely moving mice
Understanding brain function requires tools that allow precise manipulation of receptor signaling in defined cell types within intact neural circuits. Optogenetics and conventional chemogenetic approaches primarily enable cell-type-specific control of neuronal excitability using engineered receptors or ion channels. However, direct and reversible inhibition of endogenous neurotransmitter receptors in defined cell types has remained technically inaccessible. Here, we introduce native receptor-targeted chemogenetics (NARCH), a chemogenetic strategy that integrates structure-guided receptor engineering with allosteric ligand design to achieve reversible and temporally precise inhibition of endogenous receptor signaling with cell-type specificity in vivo . By applying NARCH to metabotropic glutamate receptor 1 (mGlu1), we demonstrate that mGlu1 signaling in cerebellar Purkinje cells is required for stabilization of motor learning across training sessions in freely moving mice. NARCH thus establishes a receptor-level chemogenetic framework for causal analysis of neural circuits and behavior.
Open AccessNative receptor-targeted chemogenetics enables cell-type-specific inhibition of endogenous receptors in freely moving mice
Understanding brain function requires tools that allow precise manipulation of receptor signaling in defined cell types within intact neural circuits. Optogenetics and conventional chemogenetic approaches primarily enable cell-type-specific control of neuronal excitability using engineered receptors or ion channels. However, direct and reversible inhibition of endogenous neurotransmitter receptors in defined cell types has remained technically inaccessible. Here, we introduce native receptor-targeted chemogenetics (NARCH), a chemogenetic strategy that integrates structure-guided receptor engineering with allosteric ligand design to achieve reversible and temporally precise inhibition of endogenous receptor signaling with cell-type specificity in vivo . By applying NARCH to metabotropic glutamate receptor 1 (mGlu1), we demonstrate that mGlu1 signaling in cerebellar Purkinje cells is required for stabilization of motor learning across training sessions in freely moving mice. NARCH thus establishes a receptor-level chemogenetic framework for causal analysis of neural circuits and behavior.
- Open Access
- 15 January 2026
- Published by Elsevier in NeuroImage
- Vol. 327, 121731
In vivo quantitative assessments with [11C]T-278, a PET imaging agent for diacylglycerol kinase gamma, in nonhuman primate brain
- 15 January 2026
- Published by Elsevier in NeuroImage
- Vol. 327, 121731
Open AccessIn vivo quantitative assessments with [11C]T-278, a PET imaging agent for diacylglycerol kinase gamma, in nonhuman primate brain
- Open Access
- 12 December 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (1) , 218-225
Radiosynthesis and Preclinical Evaluation of a Novel 11 C-Labeled Pyrazolopyrimidine Derivative for Positron Emission Tomography Imaging of Phosphodiesterase 2A
Phosphodiesterase 2A (PDE2A) plays a vital role in regulating cyclic nucleotide signaling by hydrolyzing cAMP and cGMP in the central nervous system (CNS). This enzymatic activity is essential for neuronal function, and PDE2A has emerged as a molecular target for neuroimaging in neuropsychiatric disorders and neurodegenerative diseases. In this study, we evaluated the novel 11C-labeled positron emission tomography (PET) radioligand [11C]1 derived from a pyrazolopyrimidine-based PDE2A inhibitor. The radiosynthesis of [11C]1 was accomplished via [11C]-methyl iodide-mediated methylation of precursor 9 under mild conditions, yielding [11C]1 with high purity (99%) and high molar activity (154 ± 66 GBq/μmol). In vitro autoradiography demonstrated high radiotracer accumulation in regions with abundant PDE2A expression, including the striatum and substantia nigra. However, dynamic PET imaging in rats showed a relatively uniform distribution throughout the brain and no significant blocking effects. Further optimization in medicinal chemistry is necessary to improve the in vivo performance of the pyrazolopyrimidine-based PDE2A tracer scaffold.
- 12 December 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (1) , 218-225
Open AccessRadiosynthesis and Preclinical Evaluation of a Novel 11 C-Labeled Pyrazolopyrimidine Derivative for Positron Emission Tomography Imaging of Phosphodiesterase 2A
Phosphodiesterase 2A (PDE2A) plays a vital role in regulating cyclic nucleotide signaling by hydrolyzing cAMP and cGMP in the central nervous system (CNS). This enzymatic activity is essential for neuronal function, and PDE2A has emerged as a molecular target for neuroimaging in neuropsychiatric disorders and neurodegenerative diseases. In this study, we evaluated the novel 11C-labeled positron emission tomography (PET) radioligand [11C]1 derived from a pyrazolopyrimidine-based PDE2A inhibitor. The radiosynthesis of [11C]1 was accomplished via [11C]-methyl iodide-mediated methylation of precursor 9 under mild conditions, yielding [11C]1 with high purity (99%) and high molar activity (154 ± 66 GBq/μmol). In vitro autoradiography demonstrated high radiotracer accumulation in regions with abundant PDE2A expression, including the striatum and substantia nigra. However, dynamic PET imaging in rats showed a relatively uniform distribution throughout the brain and no significant blocking effects. Further optimization in medicinal chemistry is necessary to improve the in vivo performance of the pyrazolopyrimidine-based PDE2A tracer scaffold.
- 6 November 2025
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 150-151, 109579
Estimation of the binding potential of the PET ligand [18F]FEDAC to translocator protein 18 kDa (TSPO) in the brain of experimental stroke model rats
- 6 November 2025
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 150-151, 109579
Estimation of the binding potential of the PET ligand [18F]FEDAC to translocator protein 18 kDa (TSPO) in the brain of experimental stroke model rats
- Open Access
- 21 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 23375-23388
Discovery of Pyrazole-Based Positron Emission Tomography Agent that Maps Histone Deacetylase 6 (HDAC6) in the Nonhuman Primate Brain
Histone deacetylase 6 (HDAC6) is a crucial target for the development of pharmaceuticals used in the treatment of neurodegenerative disorders. Here, we identified 16a as a candidate of positron emission tomography (PET) tracer for HDAC6 imaging from pyrazole derivatives, which showed strong HDAC6 affinity (Kd = 1.66 nM) and higher accumulation in the brain of wild-type mice than in HDAC6 knockout mice. Following radiolabeling with fluorine-18, PET with [18F]16a exhibited heterogeneous uptake of radioactivity, corresponding to the biological distribution of HDAC6 in the monkey brain. These radioactive distributions were homogeneously diminished by the preadministration of ACY-775, a potent inhibitor of HDAC6, suggesting that radioactive accumulation in PET images could reflect the specific binding of [18F]16a with HDAC6. Thus, [18F]16a is a promising PET tracer for HDAC6 imaging that motivates future clinical research.
- 21 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (21) , 23375-23388
Open AccessDiscovery of Pyrazole-Based Positron Emission Tomography Agent that Maps Histone Deacetylase 6 (HDAC6) in the Nonhuman Primate Brain
Histone deacetylase 6 (HDAC6) is a crucial target for the development of pharmaceuticals used in the treatment of neurodegenerative disorders. Here, we identified 16a as a candidate of positron emission tomography (PET) tracer for HDAC6 imaging from pyrazole derivatives, which showed strong HDAC6 affinity (Kd = 1.66 nM) and higher accumulation in the brain of wild-type mice than in HDAC6 knockout mice. Following radiolabeling with fluorine-18, PET with [18F]16a exhibited heterogeneous uptake of radioactivity, corresponding to the biological distribution of HDAC6 in the monkey brain. These radioactive distributions were homogeneously diminished by the preadministration of ACY-775, a potent inhibitor of HDAC6, suggesting that radioactive accumulation in PET images could reflect the specific binding of [18F]16a with HDAC6. Thus, [18F]16a is a promising PET tracer for HDAC6 imaging that motivates future clinical research.
- Open Access
- 18 August 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (9) , 1835-1843
Radiosynthesis and Preclinical Evaluation of a Carbon-11 Labeled Phosphodiesterase 7 Inhibitor for PET Neuroimaging
Dysfunction of cyclic nucleotide phosphodiesterase 7 (PDE7) has been associated with excess intracellular cAMP concentrations, fueling pathogenic processes that are implicated in neurodegenerative disorders. This study aimed to develop a suitable positron emission tomography (PET) probe that allows noninvasive mapping of PDE7 in the mammalian brain. Based on a spiro cyclohexane-1,4'-quinazolinone scaffold with known inhibitory properties toward PDE7, we designed and synthesized a carbon-11 labeling tolerant methoxy analog. The resulting PET probe, code named [11C]-P7-2104 (27), was synthesized in high molar activities (170-220 GBq/μmol) with decay-corrected radiochemical yields of 34 ± 7%. In vitro cell uptake of [11C]27 was 6-7-fold higher in PDE7 overexpressing cells compared to the controls, whereas an in vitro specificity of up to 90% was measured. Ex vivo metabolite studies revealed a high fraction of intact parent in the rat brain (98% at 5 min and 75% at 30 min postinjection). Considerable brain penetration was further corroborated by ex vivo biodistribution and PET imaging studies, the latter showing heterogenic brain uptake. While marginal blockade was observed by PET studies in rodents, a moderate, but dose-dependent, blockade was observed in the non-human primate brain following pretreatment with nonradioactive 27. Accordingly, [11C]27 will serve as a valuable lead compound for the development of a new arsenal of PDE7-targeted probes.
- 18 August 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (9) , 1835-1843
Open AccessRadiosynthesis and Preclinical Evaluation of a Carbon-11 Labeled Phosphodiesterase 7 Inhibitor for PET Neuroimaging
Dysfunction of cyclic nucleotide phosphodiesterase 7 (PDE7) has been associated with excess intracellular cAMP concentrations, fueling pathogenic processes that are implicated in neurodegenerative disorders. This study aimed to develop a suitable positron emission tomography (PET) probe that allows noninvasive mapping of PDE7 in the mammalian brain. Based on a spiro cyclohexane-1,4'-quinazolinone scaffold with known inhibitory properties toward PDE7, we designed and synthesized a carbon-11 labeling tolerant methoxy analog. The resulting PET probe, code named [11C]-P7-2104 (27), was synthesized in high molar activities (170-220 GBq/μmol) with decay-corrected radiochemical yields of 34 ± 7%. In vitro cell uptake of [11C]27 was 6-7-fold higher in PDE7 overexpressing cells compared to the controls, whereas an in vitro specificity of up to 90% was measured. Ex vivo metabolite studies revealed a high fraction of intact parent in the rat brain (98% at 5 min and 75% at 30 min postinjection). Considerable brain penetration was further corroborated by ex vivo biodistribution and PET imaging studies, the latter showing heterogenic brain uptake. While marginal blockade was observed by PET studies in rodents, a moderate, but dose-dependent, blockade was observed in the non-human primate brain following pretreatment with nonradioactive 27. Accordingly, [11C]27 will serve as a valuable lead compound for the development of a new arsenal of PDE7-targeted probes.
- 15 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (12) , 12733-12744
Development of a Novel Positron Emission Tomography Probe Deuterated [18F]FE-TMP ([18F]FE-TMP-d4), an Antagonist of Escherichia coli Dihydrofolate Reductase, for Reporter Gene Imaging of the Brain
[18F]Fluoroethoxy trimethoprim ([18F]FE-TMP, [18F]2), a unique antagonist of bacterial dihydrofolate reductase (ecDHFR), has been developed as a reporter gene imaging agent. Here, we developed new PET probes based on TMP. Simulations predicted that hydrophobic interactions around the benzene ring of 2 contributed to binding with ecDHFR. The more lipophilic fluoropropyl-TMP analog (3) showed a higher binding affinity for ecDHFR than 2. However, 18F-labeled 3 ([18F]3) underwent 18F-defluorination during PET imaging of ecDHFR-transfected mice. Subsequently, we evaluated FE-d4 analog (5) as a candidate exhibiting greater in vivo stability than 2. Metabolite analysis showed a lower contamination of radiolabeled metabolites in mouse brains with 18F-labeled 5 ([18F]5) than [18F]2. PET imaging with [18F]5 of a non-human primate brain was characterized by a distinct signal/noise ratio, which allowed in vivo visualization of brain circuits expressing the reporter gene, demonstrating the superior potential of [18F]5 as a PET probe for reporter gene imaging of the brain.
- 15 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (12) , 12733-12744
Development of a Novel Positron Emission Tomography Probe Deuterated [18F]FE-TMP ([18F]FE-TMP-d4), an Antagonist of Escherichia coli Dihydrofolate Reductase, for Reporter Gene Imaging of the Brain
[18F]Fluoroethoxy trimethoprim ([18F]FE-TMP, [18F]2), a unique antagonist of bacterial dihydrofolate reductase (ecDHFR), has been developed as a reporter gene imaging agent. Here, we developed new PET probes based on TMP. Simulations predicted that hydrophobic interactions around the benzene ring of 2 contributed to binding with ecDHFR. The more lipophilic fluoropropyl-TMP analog (3) showed a higher binding affinity for ecDHFR than 2. However, 18F-labeled 3 ([18F]3) underwent 18F-defluorination during PET imaging of ecDHFR-transfected mice. Subsequently, we evaluated FE-d4 analog (5) as a candidate exhibiting greater in vivo stability than 2. Metabolite analysis showed a lower contamination of radiolabeled metabolites in mouse brains with 18F-labeled 5 ([18F]5) than [18F]2. PET imaging with [18F]5 of a non-human primate brain was characterized by a distinct signal/noise ratio, which allowed in vivo visualization of brain circuits expressing the reporter gene, demonstrating the superior potential of [18F]5 as a PET probe for reporter gene imaging of the brain.
- 9 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (12) , 12457-12472
Radiofluorination of 2-Arylquinolin-4-yl Oxypropanamide Derivatives for TSPO Imaging in Neuroinflammatory Murine, Nonhuman Primates, and Human Brain Autoradiography with Insensitivity to the rs6971 Polymorphism
The 18 kDa translocator protein (TSPO) is a critical target for PET imaging of neuroinflammation in central nervous system (CNS) disorders; however, many clinical TSPO PET tracers are limited by sensitivity to rs6971 polymorphism. In this study, three novel fluorine-containing oxypropanamide ligands were developed, with 11 (LW1, Ki = 0.07 nM) and 12 (LW2, Ki = 0.05 nM) showing high TSPO affinity. The radiolabeled [18F]12 demonstrated superior metabolic stability, specificity, and reduced polymorphism sensitivity compared to [18F]11 in autoradiography using Tg2576, PS19 mouse models, and human brain tissues. [18F]12 was further evaluated in APP/PS1 transgenic mice and ischemic stroke rats for neuroinflammatory imaging and in healthy rhesus monkeys to access pharmacokinetics via dynamic PET with arterial sampling. The combination of excellent brain penetration, high specificity, and rs6971 insensitivity supports [18F]12 as a promising TSPO PET tracer for clinical translation.
- 9 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (12) , 12457-12472
Radiofluorination of 2-Arylquinolin-4-yl Oxypropanamide Derivatives for TSPO Imaging in Neuroinflammatory Murine, Nonhuman Primates, and Human Brain Autoradiography with Insensitivity to the rs6971 Polymorphism
The 18 kDa translocator protein (TSPO) is a critical target for PET imaging of neuroinflammation in central nervous system (CNS) disorders; however, many clinical TSPO PET tracers are limited by sensitivity to rs6971 polymorphism. In this study, three novel fluorine-containing oxypropanamide ligands were developed, with 11 (LW1, Ki = 0.07 nM) and 12 (LW2, Ki = 0.05 nM) showing high TSPO affinity. The radiolabeled [18F]12 demonstrated superior metabolic stability, specificity, and reduced polymorphism sensitivity compared to [18F]11 in autoradiography using Tg2576, PS19 mouse models, and human brain tissues. [18F]12 was further evaluated in APP/PS1 transgenic mice and ischemic stroke rats for neuroinflammatory imaging and in healthy rhesus monkeys to access pharmacokinetics via dynamic PET with arterial sampling. The combination of excellent brain penetration, high specificity, and rs6971 insensitivity supports [18F]12 as a promising TSPO PET tracer for clinical translation.
- Open Access
- 3 May 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (3) , fcae172
Potential for in vivo visualization of intracellular pH gradient in the brain using PET imaging
Intracellular pH is a valuable index for predicting neuronal damage and injury. However, no PET probe is currently available for monitoring intracellular pH in vivo. In this study, we developed a new approach for visualizing the hydrolysis rate of monoacylglycerol lipase, which is widely distributed in neurons and astrocytes throughout the brain. This approach uses PET with the new radioprobe [11C]QST-0837 (1,1,1,3,3,3-hexafluoropropan-2-yl-3-(1-phenyl-1H-pyrazol-3-yl)azetidine-1-[11C]carboxylate), a covalent inhibitor containing an azetidine carbamate skeleton for monoacylglycerol lipase. The uptake and residence of this new radioprobe depends on the intracellular pH gradient, and we evaluated this with in silico, in vitro and in vivo assessments. Molecular dynamics simulations predicted that because the azetidine carbamate moiety is close to that of water molecules, the compound containing azetidine carbamate would be more easily hydrolyzed following binding to monoacylglycerol lipase than would its analogue containing a piperidine carbamate skeleton. Interestingly, it was difficult for monoacylglycerol lipase to hydrolyze the azetidine carbamate compound under weakly acidic (pH 6) conditions because of a change in the interactions with water molecules on the carbamate moiety of their complex. Subsequently, an in vitro assessment using rat brain homogenate to confirm the molecular dynamics simulation-predicted behaviour of the azetidine carbamate compound showed that [11C]QST-0837 reacted with monoacylglycerol lipase to yield an [11C]complex, which was hydrolyzed to liberate 11CO2 as a final product. Additionally, the 11CO2 liberation rate was slower at lower pH. Finally, to indicate the feasibility of estimating how the hydrolysis rate depends on intracellular pH in vivo, we performed a PET study with [11C]QST-0837 using ischaemic rats. In our proposed in vivo compartment model, the clearance rate of radioactivity from the brain reflected the rate of [11C]QST-0837 hydrolysis (clearance through the production of 11CO2) in the brain, which was lower in a remarkably hypoxic area than in the contralateral region. In conclusion, we indicated the potential for visualization of the intracellular pH gradient in the brain using PET imaging, although some limitations remain. This approach should permit further elucidation of the pathological mechanisms involved under acidic conditions in multiple CNS disorders.
- 3 May 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (3) , fcae172
Open AccessPotential for in vivo visualization of intracellular pH gradient in the brain using PET imaging
Intracellular pH is a valuable index for predicting neuronal damage and injury. However, no PET probe is currently available for monitoring intracellular pH in vivo. In this study, we developed a new approach for visualizing the hydrolysis rate of monoacylglycerol lipase, which is widely distributed in neurons and astrocytes throughout the brain. This approach uses PET with the new radioprobe [11C]QST-0837 (1,1,1,3,3,3-hexafluoropropan-2-yl-3-(1-phenyl-1H-pyrazol-3-yl)azetidine-1-[11C]carboxylate), a covalent inhibitor containing an azetidine carbamate skeleton for monoacylglycerol lipase. The uptake and residence of this new radioprobe depends on the intracellular pH gradient, and we evaluated this with in silico, in vitro and in vivo assessments. Molecular dynamics simulations predicted that because the azetidine carbamate moiety is close to that of water molecules, the compound containing azetidine carbamate would be more easily hydrolyzed following binding to monoacylglycerol lipase than would its analogue containing a piperidine carbamate skeleton. Interestingly, it was difficult for monoacylglycerol lipase to hydrolyze the azetidine carbamate compound under weakly acidic (pH 6) conditions because of a change in the interactions with water molecules on the carbamate moiety of their complex. Subsequently, an in vitro assessment using rat brain homogenate to confirm the molecular dynamics simulation-predicted behaviour of the azetidine carbamate compound showed that [11C]QST-0837 reacted with monoacylglycerol lipase to yield an [11C]complex, which was hydrolyzed to liberate 11CO2 as a final product. Additionally, the 11CO2 liberation rate was slower at lower pH. Finally, to indicate the feasibility of estimating how the hydrolysis rate depends on intracellular pH in vivo, we performed a PET study with [11C]QST-0837 using ischaemic rats. In our proposed in vivo compartment model, the clearance rate of radioactivity from the brain reflected the rate of [11C]QST-0837 hydrolysis (clearance through the production of 11CO2) in the brain, which was lower in a remarkably hypoxic area than in the contralateral region. In conclusion, we indicated the potential for visualization of the intracellular pH gradient in the brain using PET imaging, although some limitations remain. This approach should permit further elucidation of the pathological mechanisms involved under acidic conditions in multiple CNS disorders.